Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) lost 3.32% after the company announced the issuance of a Notice of Allowance by the Chinese National Intellectual Property Administration for a patent titled “An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation”.
The patent addresses A3 Adenosine Receptor ligand usage.
The patent addresses A3 Adenosine Receptor (A3AR) ligand usage, the target receptor for Can-drug Fite’s platform technology, to reduce liver fat in non-alcoholic steatohepatitis (NASH) patients. Based on the results of a successful Phase IIa study in which Namodenoson was proven to reduce liver fat content and inhibit fibrosis, Can-Fite expects to start a Phase IIb study for the liver medication candidate Namodenoson in NASH treatment in Q3 2021.
Already Namodenoson is out-licensed in China for NASH treatment, as part of a transaction worth up to $74.5 million in milestone payments and royalties in double digits. The NASH treatment market in China is expected to hit $6.4 billion by 2027, owing to rising obesity, diabetes rates, and metabolic syndrome.
Can-Fite CEO Pnina Fishman said that as they get ready to start enrolling patients in the Phase IIb study of Namodenoson for the treatment of NASH next quarter, they are excited to expand their patent portfolio in this high-value area. Fishman added that this latest NASH patent joins several that have already been granted.
Namodenoson in Phase III study in HCC
The company is about to commence Phase III Namodenoson study to treat hepatocellular carcinoma (HCC), the most common liver cancer type, besides the Phase IIb trial for non-alcoholic steatohepatitis (NASH). The US FDA granted Namodenoson Orphan Drug Designation in the US as well as Fast Track Designation as a second-line treatment for HCC. Namodenoson has potential in melanoma, prostate, and colon cancer.